Name: Pharmacovigilance of NeuroEPO in subjects included in clinical trials. (en Inglés)
Price: 76.10 USD
Availability: InStock
Author: Estévez Iglesias, Daymys ; Pérez Ruiz, Leslie ; Viada González, Carmen
ISBN: 9786206105220

portada Pharmacovigilance of NeuroEPO in subjects included in clinical trials. (en Inglés)

Formato

Libro Físico

Autor

Carmen Viada González

Daymys Estévez Iglesias

Leslie Pérez Ruiz

Editorial

Our Knowledge Publishing

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

Dimensiones

22.9 x 15.2 x 0.3 cm

Peso

0.09 kg.

ISBN13

9786206105220

Categorías

Cuestiones generales de la medicina

Pharmacovigilance of NeuroEPO in subjects included in clinical trials. (en Inglés)

Carmen Viada González (Autor) · Daymys Estévez Iglesias (Autor) · Leslie Pérez Ruiz (Autor) · Our Knowledge Publishing · Tapa Blanda

Libro Nuevo

$ 76.10

$ 117.08

Ahorras: $ 40.98

35% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Martes 06 de Agosto y el Martes 20 de Agosto.

Lo recibirás en cualquier lugar de Ecuador entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Pharmacovigilance of NeuroEPO in subjects included in clinical trials. (en Inglés)"

Introduction: NeuroEPO is a variant of recombinant human erythropoietin with low sialic acid content, formulated for intranasal administration. Objective: to evaluate the safety of NeuroEPO, during its use in subjects included in clinical trials developed in Cuba, during the years 2013 -2020. Materials and methods: a retrospective study was conducted, based on the safety data of 356 subjects included in five completed clinical trials (25 healthy volunteers, 34 patients with diagnosis of Spinocerebellar Ataxia type 2, 127 with diagnosis of Parkinson's disease and 170 with clinical diagnosis of mild-moderate Alzheimer's disease). carried out. Events were classified according to severity, intensity, drug attitude, outcome and causality. Results: 137 (38.48 %) patients with AEs were reported, distributed in 63 types with a frequency of 162 events. Of these, 18 (28.6 %) types with a frequency of 44 (27.2 %) were related to the study drug. All were classified non-serious, mild intensity and 41 (93.2 %) with reversible outcome. Conclusions: Treatment with NeuroEPO by intranasal route was safe.